RESUMEN
Drug-induced SLE and idiopathic SLE differ in a number of important aspects, for example the male/female ratio and the age of the patients. There are also differences in incidence in different populations. The mechanism of drug-induced SLE is still largely unknown. It is generally assumed to be an allergic reaction to the drug. The database of the Netherlands Pharmacovigilance Centre Lareb contains 31 reports of SLE in relation to the use of 24 different drugs. In 3 of these cases, there was aggravation of pre-existent SLE. Infliximab and terbinafine are the most frequently reported in association with drug-induced SLE. Furthermore, the database contains a small number of reports of SLE associated with the use of antibiotics. It is difficult to determine whether all of the reported cases involve true drug-induced SLE, but a number of factors suggest that this is often the case, such as the presence or absence of skin involvement and the number of patients that recover after withdrawal of the drug. During the diagnosis of SLE, healthcare professionals should be aware of the use of drugs that might be associated with the induction of SLE.
Asunto(s)
Antibacterianos/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Lupus Eritematoso Sistémico/inducido químicamente , Naftalenos/efectos adversos , Adulto , Antibacterianos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Notificación de Enfermedades , Femenino , Humanos , Infliximab , Masculino , Persona de Mediana Edad , Naftalenos/uso terapéutico , TerbinafinaRESUMEN
An otherwise healthy 31-year-old woman with allergic rhinoconjunctivitis developed considerable swelling of the floor of her mouth after sublingual allergen-specific immunotherapy with the hyposensitization product 'Slit One grass pollen'. After discontinuation, complaints disappeared and she was successfully put on a regimen of subcutaneous immunotherapy. Despite a lack of reports of serious adverse reactions in clinical trials, the Inspectorate of Health Care and The Netherlands Pharmacovigilance Centre Lareb received several reports of sometimes serious localized reactions to oral and sublingual allergen-specific immunotherapy. Under-reporting is likely since local reactions are more or less expected. Caution should be exercised with allergen treatment, even in the case of non-invasive administration.